(E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate | 1261180-90-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate
• 英文别名: ethyl (E)-2-acetamido-3-(dimethylamino)but-2-enoate
• CAS: 1261180-90-8
• 化学式: C₁₀H₁₈N₂O₃
• 分子量: 214.265
• InChiKey: SNYMWQPXJDJFQL-VQHVLOKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate 在 甲醇 、 ammonium sulfate 、 溶剂黄146 、 六甲基二硅氮烷 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 12.0h， 生成 Sodium;1-cyclopentyl-2,5-dimethylimidazole-4-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT_2A Receptor and 5-HT Transporter

  摘要：

  Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several neurological conditions, and potent selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT2A/2C and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC50 values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use.

  DOI：

  10.1021/jm200682b
• 作为产物：
  描述：

  乙醇 、 4-(1-(dimethylamino)ethylidene)-2-methyloxazol-5(4H)-one 在 sodium hydride 作用下， 以 mineral oil 为溶剂， 反应 1.0h， 生成 (E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate
  参考文献：
  名称：

  Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT_2A Receptor and 5-HT Transporter

  摘要：

  Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several neurological conditions, and potent selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT2A/2C and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC50 values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use.

  DOI：

  10.1021/jm200682b

文献信息

• NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Lee Jinhwa

  公开号：US20120115881A1

  公开（公告）日：2012-05-10

  A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

  本发明提供了一种新的含有芳基哌嗪基的咪唑-4-羧酰胺衍生物或其药学上可接受的盐，并且提供了一种以其为活性成分的制药组合物，用于预防或治疗抑郁症。
• Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
  申请人：Lee Jinhwa

  公开号：US08835436B2

  公开（公告）日：2014-09-16

  A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

  本发明提供了一种新的含有芳基哌嗪基和咪唑-4-羧酰胺衍生物或其药学上可接受的盐，以及一种包含该衍生物作为活性成分的药物组合物，用于预防或治疗抑郁症。
• [EN] NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] NOUVEAUX DÉRIVÉS IMIDAZOLE-4-CARBOXAMIDE CONTENANT DE L'ARYLPIPÉRAZINE ET COMPOSITION PHARMACEUTIQUE CONTENANT CES DÉRIVÉS
  申请人：GREEN CROSS CORP

  公开号：WO2011005052A8

  公开（公告）日：2012-02-02
• [EN] NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] NOUVEAUX DÉRIVÉS IMIDAZOLE-4-CARBOXAMIDE CONTENANT DE L’ARYLPIPÉRAZINE ET COMPOSITION PHARMACEUTIQUE CONTENANT CES DÉRIVÉS
  申请人：GREEN CROSS CORP

  公开号：WO2011005052A2

  公开（公告）日：2011-01-13

  A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
• Design and Synthesis of Novel Arylpiperazine Derivatives Containing the Imidazole Core Targeting 5-HT_2A Receptor and 5-HT Transporter
  作者：Hee Jeong Seo、Eun-Jung Park、Min Ju Kim、Suk Youn Kang、Suk Ho Lee、Hyun Jung Kim、Ki Nam Lee、Myung Eun Jung、MinWoo Lee、Mi-Soon Kim、Eun-Jung Son、Woo-Kyu Park、Jeongmin Kim、Jinhwa Lee

  DOI：10.1021/jm200682b

  日期：2011.9.22

  Serotonin antagonist reuptake inhibitor (SARI) drugs that block both 5-HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A/2C receptor has been implicated in several neurological conditions, and potent selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS diseases such as depression. An imidazole moiety usually provides good pharmacokinetic properties as a drug substance, and thus considerable efforts have been devoted to develop imidazole derivatives into drug candidates. The imidazole series of compounds was evaluated against 5-HT2A/2C and serotonin reuptake inhibition. A few of the compounds in the series showed promising IC50 values and antidepressant-like effect in in vivo forced swimming test (FST). On the basis of these results, further lead optimization studies resulted in identifying promising compounds potentially for therapeutic use.